Abstral , which is already marketed by ProStrakan across the European markets has got the US Food and Drug Administration approval in January 2011.
Abstral is based on Orexo’s sublingual tablet technology and the analgesic, fentanyl.
Orexo president and CEO Anders Lundstrom said they are pleased that Abstral has been launched on the US market for fast and effective relief from breakthrough pain.